scholarly article | Q13442814 |
P356 | DOI | 10.1586/ERI.12.114 |
P698 | PubMed publication ID | 23113664 |
P2093 | author name string | Andy I M Hoepelman | |
Annemarie M J Wensing | |||
Steven F L van Lelyveld | |||
P2860 | cites work | Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. | Q44533053 |
Transmission of drug-resistant HIV-1 is stabilizing in Europe | Q44591236 | ||
Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy | Q45853423 | ||
Phenotypic expressions of CCR5-delta32/delta32 homozygosity | Q45863096 | ||
The evolution of coreceptor tropism in HIV-infected patients interrupting suppressive antiretroviral therapy. | Q53779598 | ||
Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals | Q22242705 | ||
Identification of a major co-receptor for primary isolates of HIV-1 | Q22251282 | ||
Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies | Q24597052 | ||
Hepatotoxicity observed in clinical trials of aplaviroc (GW873140) | Q24641929 | ||
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators | Q29547281 | ||
Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection | Q29614956 | ||
Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study | Q33521080 | ||
Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study | Q34045403 | ||
Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity | Q34123595 | ||
HIV Infection, Inflammation, Immunosenescence, and Aging | Q34150710 | ||
Low mortality in HIV-infected patients starting highly active antiretroviral therapy: a comparison with the general population | Q34547175 | ||
Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection | Q34597895 | ||
A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1. | Q34607511 | ||
HIV entry inhibitors. | Q34654433 | ||
Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: a meta-analysis of 4 cohorts in the US epidemic | Q34733732 | ||
Maraviroc for previously treated patients with R5 HIV-1 infection | Q34806062 | ||
Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism | Q35635933 | ||
Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2. | Q35875096 | ||
Maraviroc in treatment-experienced patients with HIV-1 infection - experience from routine clinical practice | Q35959156 | ||
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration | Q37208045 | ||
CCR5 antagonism in HIV infection: ways, effects, and side effects | Q37590614 | ||
Definition and epidemiology of late presentation in Europe | Q37742324 | ||
Maraviroc: a review of its use in the management of CCR5-tropic HIV-1 infection | Q37762248 | ||
European guidelines on the clinical management of HIV-1 tropism testing | Q37856554 | ||
Primary resistance to maraviroc in a large set of R5-V3 viral sequences from HIV-1-infected patients | Q39443078 | ||
Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211 | Q39495730 | ||
HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro | Q39501136 | ||
Maraviroc is able to inhibit dual-R5 viruses in a dual/mixed HIV-1-infected patient | Q39502552 | ||
Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. | Q41557849 | ||
Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients | Q41991922 | ||
Correlates of lending needles/syringes among HIV-seropositive injection drug users | Q42640169 | ||
Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies | Q42926976 | ||
Long-term immunovirogical effect and tolerability of a maraviroc-containing regimen in routine clinical practice | Q42966027 | ||
Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience | Q43162451 | ||
P433 | issue | 11 | |
P921 | main subject | anti-retroviral agent | Q50430310 |
P304 | page(s) | 1241-1247 | |
P577 | publication date | 2012-10-31 | |
P1433 | published in | Expert Review of Anti-infective Therapy | Q15734432 |
P1476 | title | The MOTIVATE trials: maraviroc therapy in antiretroviral treatment-experienced HIV-1-infected patients | |
P478 | volume | 10 |
Q38803127 | CCR5 receptor antagonists in preclinical to phase II clinical development for treatment of HIV. |
Q30364312 | Developments in HIV-1 immunotherapy and therapeutic vaccination. |
Q92856694 | Entanglement of CCR5 and Alzheimer's Disease |
Q53707006 | High Virologic Failure Rates with Maraviroc-Based Salvage Regimens Among Indian Patients: A Preliminary Analysis-Maraviroc Effectiveness in HIV-1 Subtype C. |
Search more.